Antitumor Activity of Ribonuclease Multimers Created by Site-Specific Covalent Tethering

Thomas J. Rutkoski,‡ John A. Kink,§ Laura E. Strong,§ Christine I. Schilling,‖ and Ronald T. Raines,*†,†#

Departments of Biochemistry and Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, Quintessence Biosciences, Inc., 505 South Rosa Road, Madison, Wisconsin 53719, and Institut für Organische Chemie, Universität Karlsruhe (TH), Fritz-Haber Weg 6, D-76131 Karlsruhe, Germany. Received June 28, 2010; Revised Manuscript Received July 21, 2010

Site-specific cross-linking can generate homogeneous multimeric proteins of defined valency. Pancreatic-type ribonucleases are an especially attractive target, as their natural dimers can enter mammalian cells, evade the cytosolic ribonuclease inhibitor (RI), and exert their toxic ribonucleolytic activity. Here, we report on the use of eight distinct thiol-reactive cross-linking reagents to produce dimeric and trimeric conjugates of four pancreatic-type ribonucleases. Both the site of conjugation and, to a lesser extent, the propinquity of the monomers within the conjugate modulate affinity for RI, and hence cytotoxicity. Still, the cytotoxicity of the multimers is confounded in vitro by their increased hydrodynamic radius, which attenuates cytosolic entry. A monomeric RI-evasive variant of bovine pancreatic ribonuclease (RNase A) inhibits the growth of human prostate and lung tumors in mice. An RI-evasive trimeric conjugate inhibits tumor growth at a lower dose and with less frequent administration than does the monomer. This effect is attributable to an enhanced persistence of the trimers in circulation. On a molecular basis, the trimer is ~300-fold more efficacious and as well tolerated as erlotinib, which is in clinical use for the treatment of lung cancer. These data encourage the development of mammalian ribonucleases for the treatment of human cancers.

INTRODUCTION

Bovine seminal ribonuclease (BS-RNase)† and several amphibian ribonucleases, including ranpirnase (Onconase; ONC), exhibit innate antitumoral activity (1-3). ONC has demonstrated responses in patients with breast, non-small cell lung, and esophageal cancer, and unresectable malignant mesothelioma (4-6). Although these two homologues of bovine pancreatic ribonuclease (RNase A (7)) differ dramatically in both primary and quaternary structure (8, 9), they both evade inhibition by ribonuclease inhibitor (RI (10)), a protein that resides in the cytosol of mammalian cells. BS-RNase is a natural dimer that evades RI by steric repulsion (11); whereas ONC is a small monomer whose truncated surface loops cannot interact intimately with RI (12). The ability to retain ribonucleolytic activity in the presence of RI is a primary determinant of the cytotoxicity of BS-RNase, ONC, and engineered ribonucleases (13). Prior to the discovery of BS-RNase (14), lyophilization of solutions of RNase A from aqueous acetic acid was found to yield dimers and higher order oligomers of RNase A (15). These oligomers of RNase A—as large as nonameric (16)—formed by domain swapping of the N- or C-termini, or both (17), and displayed antitumoral activity concomitant with their degree of oligomerization: tetramers > trimers > dimers (18). Tandem dimers of RNase A are likewise toxic to cancer cells (19).

In contrast to domain-swapping, covalent cross-linking does not allow for monomer dissociation (20, 21). Dimers of RNase A formed by cross-linking with amine-reactive imido esters, inhibit tumor cell proliferation in vitro (22), exhibit antitumoral activity in mice (23, 24), and have enhanced persistence in the circulation of rats (25). Cross-linked trimers of RNase A generated with a dimethyl suberimidate linker displayed higher toxicity towards a cervical carcinoma cell line than did cross-linked dimers (26).

Lysine is a common residue. RNase A contains 10 lysine residues, as well as an N-terminal amino group. Accordingly, a disadvantage of using amine-reactive reagents to cross-link RNase A is the heterogeneity of the ensuing products. Moreover, the amino group in the side-chain of Lys41 has a low pKₐ of ~8.8 (27) and is thus especially reactive. Its modification can reduce catalytic proficiency by 10⁴-fold (28) and obviate cytotoxicity (29).

Previously, we used dibromobimane (1) (Figure 1) to prepare a BS-RNase dimer by forming thioether bonds at a particular cysteine residue (31). We found this dimer to be toxic to cancer cells in vitro, but did not determine its affinity for RI. Guided by the structure of the RI•RNase A complex (Figure 2), Youle and co-workers generated homogeneous homodimeric conjugates of both human pancreatic ribonuclease (RNase 1) and
Here, we describe the semisynthesis and characterization of 13 dimeric and trimeric ribonuclease conjugates, derived from cross-linkers 1–8 and RNase A, BS-RNase, RNase 1, and ONC. We show that the choice of cross-linker as well as the site and valency of cross-linking affect the toxic activity toward cancer cells. The results have important implications for the development of ribonucleases as cancer chemotherapeutic agents.

MATERIALS AND METHODS

Materials. Protein Production and Characterization. E. coli BL21(DE3) cells, and pET22b (+) and pET27b (+) plasmids were from Novagen (Madison, WI). K-562 (derived from a continuous human chronic myelogenous leukemia line), DU 145 (human prostate carcinoma), and A549 (human non-small cell lung carcinoma) cells were from the American Type Culture Collection (ATCC; Manassass, VA). Cell culture medium, Dulbecco’s phosphate-buffered saline (DPBS), antibiotics, trypsin, and fetal bovine serum (FBS) were from Invitrogen (Carlsbad, CA). [methyl-3H]Thymidine (6.7 Ci/mmol) was from PerkinElmer (Boston, MA). Oligonucleotides for site-directed mutagenesis and sequencing, and the ribonuclease substrates, 6-FAM-dArUdAdA-6-TAMRA and 6-FAM-dArUdGdA-6-TAMRA, were from Integrated DNA Technologies (Coralville, IA).

1,6-Bis(maleimido)hexane (2), 1,2-bis(maleimido)ethane (3), tris(N-maleimidoethyl)amine (8), and N-ethylmaleimide were from Thermo Fisher Scientific (Rockford, IL). 1,2-Bis(maleimido)benzene (4), 1,3-bis(maleimido)benzene (5), and 1,4-bis(maleimido)benzene (6) were from Sigma-Aldrich. Dibromobimane (1) was from Molecular Probes (Eugene, OR).

FPLC HiLoad 26/60 Superdex G75 and G200 gel-filtration columns, HiTrap Desalting, SP, and Q columns were from GE Healthcare (Uppsala, Sweden). Gel-filtration standards, SDS-PAGE molecular-weight standards, and precast gels for poly(acrylamide) gel electrophoresis were from BioRad (Hercules, CA). Flat-bottom, black polystyrene (PS), Costar assay plates (96-well) with nonbinding surface (NBS) were from Corning (Acton, MA). Molecular biology-grade bovine serum albumin (BSA) was obtained as a 20 mg/mL solution from Sigma-Aldrich (St. Louis, MO). Fluorometric enzymatic activity measurements were made using 4.5 mL methacrylate cuvettes from VWR (West Chester, PA). All other chemicals used were of commercial reagent grade or better, and were used without further purification.

Chemical Synthesis. DMF was drawn from a Baker CYCLE-TAINER solvent delivery system. All other reagents were from Sigma-Aldrich or Fisher Scientific (Hanover Park, IL) and used without further purification. Thin-layer chromatography was performed using aluminum-backed plates coated with silica gel containing F254 phosphor and visualized by UV illumination or staining with I2, ceric ammonium molybdate, or phosphomolybdic acid. NMR spectra were obtained with a Bruker DMX-400 Avance spectrometer at the National Magnetic Resonance Facility at Madison (NMRFAM).

Xenograft Studies. Erlotinib hydrochloride (Tarceva) was from Genentech (South San Francisco, CA); docetaxel and cisplatin were from Sigma-Aldrich. Homozygous (nullus) male Balb/c (−/−) mice were from Harlan Sprague–Dawley (Indianapolis, IN).

Instrumentation. [methyl-3H]Thymidine incorporation into K-562 and A549 genomic DNA was quantitated by scintillation counting using a Microbeta TriLux liquid scintillation and luminescence counter (PerkinElmer, Wellesley, MA). The molecular mass of ribonuclease variants and multimeric conjugates was confirmed by MALDI-TOF mass spectrometry using 3,5-dimethoxy-4-hydroxycinnamic acid as a matrix and a Voyager-DE-PRO Biospectrometry Workstation (Applied Bio-
Scheme 1

Antitumor Activity of Ribonuclease Multimers

Bioconjugate Chem., Vol. 21, No. 9, 2010 1693
(i.e., fully reduced) for up to one month following purification and was not used beyond this time without repurification.

After their purification, ribonucleases and RI migrated as single bands during SDS-PAGE (e.g., Supporting Information Figure S1). The identity and integrity of purified ribonuclease variants was confirmed by MALDI-TOF mass spectrometry.

**Semisynthesis of Ribonuclease Dimers and Trimmers.** The pH of the solution containing NTB-protected ribonucleases in HiTrap SP elution buffer was adjusted from 5.0 to ~8.0 by the addition of either 10× DPBS (to 10% v/v) or 1.0 M Tris—HCl buffer at pH 8.0 (to 8—10% v/v). Deprotection by the addition of DTT (5—10 equiv) resulted in the generation of the yellow 2-nitro-5-thiobenzoate anion (53). Ribonucleases were separated from small molecules using a HiTrap desalting column that had been equilibrated with DPBS containing EDTA (1 mM).

**Semisynthetic Dimers.** Stock solutions (20—100 mM) of cross-linkers 3—6 and 1 were prepared in DMF, and 0.6 equiv was added to a solution containing a deprotected ribonuclease (50—250 µM). This substoichiometric amount of linker was found to produce the desired dimeric (or trimeric) conjugates in high yield, as reported previously for the dimerization of C31S BS-RNase (54). A 0.6—5.0-fold molar excess of linker favored the production of a bis(maleimide)-derivatized ribonuclease monomer; a >10-fold molar excess of linker resulted in the undesirable nonspecific modification of the ε-amino group of lysine residues, despite the maleimido group being >10-fold more reactive with thiols than amines at pH 7 (55). Conjugation reaction mixtures were protected from light, and reactions were allowed to proceed at room temperature for 2 h or overnight at 4°C. Reactions were terminated by the addition of DTT (5 equiv versus ribonuclease). The resulting crude reaction mixture was applied to a HiLoad 26/60 G75 Superdex gel-filtration column and eluted with 50 mM NaOAc buffer at pH 5.0 containing NaCl (0.1 M) and NaN3 (0.05% w/v). Fractions were analyzed by SDS-PAGE to distinguish monomeric and multimeric species, and then combined to yield the final desired conjugate at ≥95% homogeneity. Typical yields for the production of homodimers and homotrimers were 70% and 50%, respectively. Semisynthetic variants were dialyzed exhaustively against DPBS prior to further biochemical characterization.

**Semisynthetic Trimmers.** Trimeric ribonuclease conjugates were synthesized in the manner described above for dimeric conjugates, except that the tris(maleimide)-containing linkers in DMF were added to DPBS containing ribonucleases (50—250 µM) at 0.4 mol equiv (8) or 2.0 mol equiv (7).

**Modification of Ribonuclease with N-Ethylmaleimide.** To enable comparisons of G88C RNase A and G89C RNase 1 to the wild-type enzymes, these variants were modified with N-ethylmaleimide (NEM) under conditions similar to those used for the semisynthesis of dimers and trimers, except that NEM (5 equiv from a 100 mM stock solution in DMF) was added to the deprotected protein that had been desalted into DPBS. The reaction mixture was protected from light, and the reaction was allowed to proceed overnight at 4°C and then quenched by the addition of DTT (final concentration of 1 mM). The reaction mixture was then diluted 10-fold with NaOAc buffer (50 mM) at pH 5.0, applied to a HiTrap SP cation-exchange column, and eluted with a linear gradient of NaCl (0—0.4 M). The masses of the resulting ribonuclease—NEM conjugates were confirmed by MALDI-TOF mass spectrometry.

**Biochemical Characterization of Ribonuclease Dimers and Trimmers.** The succinimidyl thioether formed by conjugation of a thiol and maleimide is susceptible to a low rate of spontaneous hydrolysis (56). The products are isomeric succinimide acid thioethers that bear an additional carboxylate group, which could obfuscate our analyses. Accordingly, ribonuclease conjugates were used within 3 months of their semisynthesis.

**Ribonucleolytic Activity.** The enzymatic activity of ribonucleases was determined by assaying their ability to catalyze the cleavage of the hypersensitive fluorogenic substrate 6-FAM-dArUdAdA-6-TAMRA (20 nM) (λex = 493 nm; λem = 515 nm) (57). Assays were carried out at ambient temperature in DPBS (2.0 mL) containing BSA (0.1 mg/mL) to prevent the nonspecific binding of ribonuclease to the cuvette. Values of $k_{cat}/K_M$ were obtained with the equation

$$k_{cat}/K_M = \left( \frac{\Delta I/\Delta t}{I_{max} - I_0} \right) [E]$$  \tag{1}\]

where $\Delta I/\Delta t$ is the initial reaction velocity for cleavage of 6-FAM-dArUdAdA-6-TAMRA upon addition of ribonuclease (E) to the cuvette, and $I_0$ and $I_{max}$ are, respectively, the fluorescence intensities prior to enzyme addition and following the complete cleavage of substrate by addition of excess RNase A. Activity values for ONC and its conjugates were determined likewise using the substrate 6-FAM-dArUdGdA-6-TAMRA (50 nM) (58).

**Binding by RI.** The affinity of ribonucleases for RI was determined directly by using a fluorescence-based competition assay, as described previously (52). For the unlabeled competing multimeric ribonuclease conjugates, the molar concentration used was that of the constituent active sites and not that of the entire conjugate.

**Inhibition of Ribonucleolytic Activity by RI.** 2-fold serial dilutions of RI (2 µM to 1 pM) were prepared in 10 mM MOPS buffer at pH 7.1 containing NaCl (0.138 M), BSA (0.1 mg/mL), and DTT (5 mM) using Eppendorf Protein LoBind tubes. These RI-containing serial dilutions were delivered (50 µL/well) to a 96-well plate. Ribonucleases and their conjugates were diluted in the same buffer and added to the RI-containing wells (50 µL/well; typical final working concentration: 15 pM active site). Plates were incubated for at least 30 min at ambient temperature prior to the addition of fluorogenic substrate (6-FAM-dArUdAdA-6-TAMRA; final concentration: 50 nM) to initiate the assay. The plate was shaken briefly (30 s), and the fluorescence intensity was measured at 30 s intervals for 5 min on a microplate reader using a FITC filter set (excitation at 485 nm with a 14 nm bandwidth; emission at 535 nm with a 25 nm bandwidth; dichroic mirror cutoff at 505 nm). An identical quantity of 6-FAM-dArUdGdA-6-TAMRA was cleaved with an excess amount of ribonuclease (>10 nM), and the final fluorescence was measured to ensure that <10% of the total substrate was degraded over the course of the activity assays. Additionally, an aliquot of the untreated substrate was assayed at the end of the experiment to confirm that it had not degraded appreciably during the course of the experiment, which would be indicative of ribonuclease contamination. Initial slope values were obtained from the data points by linear regression. Relative activity values were determined by comparison to a control containing no RI. Relative activity plots were fitted by nonlinear regression to a sigmoidal variable-slope curve using the equation

$$y = F_B + \frac{F_T - F_B}{1 + 10^{(\text{log}(K_I) - \text{log}(RI))}}$$  \tag{2}\]

In eq 2, $h$ is the slope of the curve, and $F_T$ and $F_B$ correspond to the maximum relative activities at both low and high concentrations of RI, respectively.

**Gel-Filtration Analysis.** Ribonucleases (1 mL of a 1 mg/mL solution in gel-filtration buffer) were applied to a HiLoad 26/60 Superdex G200 gel-filtration column and eluted with NaOAc buffer (50 mM) at pH 5.0 containing NaCl (0.10 M) and NaN3 (0.05% w/v) at a flow rate of 4 mL/min. Gel-filtration standards were prepared and separated by chromatography using the same column.
Conformational Stability. The conformational stability of dimers and trimers of RNase A was determined by measuring their $T_m$ value, which is the temperature at the midpoint of the transition between the folded and unfolded states. Protein was dialyzed exhaustively against DPBS and diluted to a concentration of $\sim 25 \mu M$ in DPBS. Assays were performed by slow incremental heating (0.15 °C/min from 25–80 °C) and monitoring of the absorbance at 287 nm, which decreases upon RNase A denaturation (59, 60). Data were collected and analyzed with the program THERMAL from Varian Analytical Instruments (Walnut Creek, CA), which fitted the data to a two-state process and enabled the determination of the value of $T_m$ (61).

Inhibition of Tumor Cell Proliferation In Vitro. Pancreatic-type ribonucleases can inhibit tumor cell proliferation by evoking apoptosis (62). This cytotoxic activity was assessed by measuring the effect of ribonucleases on the incorporation of [methyl- $^3$H]-thymidine into the nascent DNA of K-562 cells, as described previously (37). Cells were grown in Roswell Park Memorial Institute 1640 medium (Mediatech, Herndon, VA). Cell-proliferation assays were performed at least three times in triplicate. Each data point represents the mean ($\pm$ S.E) of three or more experimental values. Values of IC$_{50}$, which is the concentration of ribonucleases that decreases cell proliferation to 50%, were calculated by fitting the data using nonlinear regression to a sigmoidal dose-response curve (eq 3).

$$y = \frac{100\%}{1 + 10^{\log IC_{50} - \log (ribonuclease) / h}}$$

In eq 3, $y$ is the DNA synthesis following a 4 h [methyl- $^3$H]-thymidine pulse, and $h$ is the slope of the curve.

Inhibition of Tumor Cell Proliferation In Vivo. Trimeric ribonucleases were tested for their ability to suppress the growth of human tumors implanted into the flanks of nude mice. DU 145 cells (prostate cancer) and A549 cells (non-small cell lung cancer) were selected for both their ability to proliferate in mice and their low rate of spontaneous regression. Moreover, each line represents a clinically relevant target that is used often in the testing of new chemotherapeutic agents.

DU 145 cells were grown in Dulbecco’s modified Eagle’s medium (ATCC) containing FBS (10% v/v); A549 cells were grown in F12K medium (ATCC) containing FBS (10% v/v). Cells were implanted into the right rear flank of 5–6 week old male homozygous (nu/nu) nude mice. Tumors were allowed to grow to a volume of $\geq 75 \text{ mm}^3$ before the initiation of treatment. All the test compounds were diluted in vehicle (DPBS), and one set of animals was treated with vehicle alone on the dosing schedule with greatest frequency. All treatments were administered either by intraperitoneal injection (i.p.) or orally with a gavage needle (p.o.); the volume of administered solution was based upon the body weight of the animal (10 μL/g). Treatment with all agents was ongoing throughout the entire experiment.

(G88C RNase A)$_3$–8 was used to treat the DU 145 and A549 xenograft models. Mice in the A549 xenograft model were each implanted with 4 $\times$ 10$^6$ cells; treatment was administered at a dose of 25 mg/kg (i.p., 1 $\times$ wk). Mice in the DU 145 xenograft model each received 3 $\times$ 10$^6$ cells; again, treatment was administered at a dose of 25 mg/kg (i.p., 1 $\times$ wk). Mice in the A549 xenograft model were also treated with (G89C RNase 1)$_3$–8 at doses of 7.5 and 75 mg/kg (i.p., 1 $\times$ wk).

Mice treated with trimeric RNase A or RNase 1 were compared with mice treated with monomeric K7A/D38R/R39D/G88R RNase A at doses of 5, 15, and 45 mg/kg (i.p., qd $\times$5) and 75 mg/kg (i.p., 1 $\times$ wk), and monomeric ONC at a dose of 5 mg/kg (i.p., 1 $\times$ wk), as well as the approved chemotherapeutic agents docetaxel (15 mg/kg; i.p., 1 $\times$ wk), cisplatin (6 mg/kg; i.p., 1 $\times$ wk), and erlotinib (100 mg/kg; p.o., 2 $\times$ wk).

Tumor size was measured twice weekly using calipers, and tumor volume (mm$^3$) was estimated by using the formula for a spheroid (eq 4).

$$\text{volume} = \frac{l \times w^2}{2}$$ (4)

The percent tumor growth inhibition (% TGI) was calculated with eq 5.

$$\% \text{TGI} = \left(1 - \left(\frac{\text{volume}_{\text{final}} - \text{volume}_{\text{initial,treated}}}{\text{volume}_{\text{final}} - \text{volume}_{\text{initial,control}}}\right)\right) \times 100$$ (5)

RESULTS

Conformational Stability. To maintain its biological activity, a ribonuclease must maintain its native tertiary structure (63). To assess whether the covalent tethering of ribonucleases into dimers or trimers compromises their conformational stability, we determined the $T_m$ values of G88C RNase A–NEM, (G88C RNase A)$_3$–3 and (G88C RNase A)$_3$–8 (Table 1). All three had $T_m$ values nearly indistinguishable from that of RNase A (Supporting Information Figure S2; Table 1). Thus, multimerization did not appear to be deleterious to the conformational stability of these conjugates. No evidence of cooperative unfolding was observed for dimeric or trimeric conjugates.

Ribonucleolytic Activity. Site-specific covalent tethering of mammalian ribonucleases had a negligible effect on their ribonucleolytic activity (Table 1). Most multimeric conjugates as well as G88C RNase A–NEM exhibited $k_d$/K$_M$ values (per active site) that were within error of that of RNase A. Exceptions were (G88C RNase A)$_3$–4, (G88C RNase A)$_3$–2, and trimeric conjugates of G88C RNase A prepared with either of the homotrifunctional linkers (7 or 8), which displayed $\sim 2$-fold increased activity per active site toward the 6-FAM-dArUdAdA-6-TAMRA substrate. The S72C ONC trimer displayed the largest change in activity upon trimerization, as its $k_d$/K$_M$ value per active site was nearly 7-fold higher than that of ONC.

Affinity for Ribonuclease Inhibitor. Dimeric and trimeric ribonuclease conjugates could conceivably be bound by more than one RI molecule. In addition, the initial binding of one RI molecule to the conjugate is likely to influence the likelihood of subsequent binding events or preclude subsequent RI-binding entirely. The fluorescence-based competition assay used herein did not report on the stoichiometry of RI-binding or determine microscopic values of K$_d$. Hence, only values of apparent K$_d$ (K in) are reported for the various conjugates.

The K$_d$ = 1.8 nM obtained for G88R RNase A (Table 1) was in gratifying agreement with values obtained previously (38, 52). G88C RNase A–NEM exhibited a nearly equivalent affinity for RI, having a K$_d = 1.4$ nM. Among the dimeric conjugates, (G88C RNase A)$_2$–4 had the lowest affinity for RI, with K$_d' = 18$ nM. With the exception of (G88C RNase A)$_2$–2 (K$_d' = 2.6$ nM), the remaining dimeric conjugates of G88C RNase A all had similar affinity for RI, with K$_d' = 8.2–14$ nM. Each trimeric conjugate of G88C RNase A displayed a significantly different affinity for RI. Those prepared with the novel tris(maleimide) linker 7 were substantially more evasive than those prepared with 8, with K$_d' = 39$ and 17 nM, respectively. In general, trimeric conjugates of G88C RNase A had a lower affinity for RI than did dimers of G88C RNase A. (BS-RNase)$_3$–8 trimeric conjugates were the most RI-evasive of the conjugates assayed, having K$_d' = 84$ nM. Trimers of A19C RNase A, which are tethered outside of the RI interface, possessed an affinity for RI that was sufficiently high to preclude quantitation in our assay (K$_d' < 1.4$ nM).
Table 1. In Vitro Attributes of Ribonucleases and Their Conjugates

<table>
<thead>
<tr>
<th>ribonuclease</th>
<th>$T_m$ (°C)</th>
<th>$k_{cat}/K_M$ (10^6 M⁻¹s⁻¹)</th>
<th>$K_i$ (µM)</th>
<th>IC50 (µM)</th>
<th>IC50 (µM)</th>
<th>Z</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNase A</td>
<td>64</td>
<td>6.4 ± 0.3</td>
<td>4.4 ± 10⁻⁵</td>
<td>&gt;25</td>
<td>&gt;25</td>
<td>+4</td>
</tr>
<tr>
<td>G88R RNase A</td>
<td>63</td>
<td>8.2 ± 0.2</td>
<td>1.8 ± 0.3</td>
<td>3.3 ± 0.1</td>
<td>3.4 ± 0.2</td>
<td>+5</td>
</tr>
<tr>
<td>G88C RNase A-NEM</td>
<td>64</td>
<td>6.8 ± 0.1</td>
<td>1.4 ± 0.4</td>
<td>28 ± 2</td>
<td>28 ± 2</td>
<td>+4</td>
</tr>
<tr>
<td>(G88C RNase A)₃⁻¹</td>
<td>ND †</td>
<td>12 ± 1</td>
<td>8.2 ± 0.2</td>
<td>22 ± 3</td>
<td>44 ± 8</td>
<td>+8</td>
</tr>
<tr>
<td>(G88C RNase A)₂⁻²</td>
<td>ND</td>
<td>11 ± 1</td>
<td>2.6 ± 0.2</td>
<td>25 ± 1</td>
<td>25 ± 1</td>
<td>+8</td>
</tr>
<tr>
<td>(G88C RNase A)₃⁻³</td>
<td>ND</td>
<td>6.6 ± 0.6</td>
<td>9.6 ± 0.4</td>
<td>11 ± 1</td>
<td>21 ± 8</td>
<td>+8</td>
</tr>
<tr>
<td>(G88C RNase A)₄⁻⁴</td>
<td>ND</td>
<td>7.4 ± 0.5</td>
<td>18 ± 2</td>
<td>10 ± 1</td>
<td>20 ± 8</td>
<td>+8</td>
</tr>
<tr>
<td>(G88C RNase A)₂⁻⁵</td>
<td>ND</td>
<td>8.6 ± 0.1</td>
<td>8.6 ± 1.6</td>
<td>14 ± 1</td>
<td>27 ± 8</td>
<td>+8</td>
</tr>
<tr>
<td>(G88C RNase A)₃⁻⁶</td>
<td>ND</td>
<td>5.5 ± 0.03</td>
<td>14 ± 3</td>
<td>27 ± 2</td>
<td>55 ± 8</td>
<td>+8</td>
</tr>
<tr>
<td>(G88C RNase A)₄⁻⁷</td>
<td>ND</td>
<td>12 ± 1</td>
<td>39 ± 3</td>
<td>16 ± 1</td>
<td>48 ± 12</td>
<td>+8</td>
</tr>
<tr>
<td>(G88C RNase A)₅⁻⁸</td>
<td>ND</td>
<td>16 ± 0.4</td>
<td>17 ± 1</td>
<td>8.6 ± 0.5</td>
<td>27 ± 13</td>
<td>+13</td>
</tr>
<tr>
<td>(A19C RNase A)²⁻⁸</td>
<td>ND</td>
<td>7.5 ± 0.4</td>
<td>&lt;1.4</td>
<td>&gt;25</td>
<td>&gt;25</td>
<td>+13</td>
</tr>
<tr>
<td>(D38R/R39D/N67R/G88C RNase A)₃⁻⁸</td>
<td>ND</td>
<td>8.4 ± 0.3</td>
<td>ND</td>
<td>1.0 ± 0.1</td>
<td>3.3 ± 16</td>
<td>+16</td>
</tr>
<tr>
<td>(C31A/C32A/G88C BS-RNase)⁻⁸</td>
<td>ND</td>
<td>5.8 ± 0.3</td>
<td>84 ± 12</td>
<td>0.78 ± 0.05</td>
<td>2.1 ± 28</td>
<td>+28</td>
</tr>
<tr>
<td>RNase 1</td>
<td>58</td>
<td>29 ± 1</td>
<td>2.9 × 10⁻⁷</td>
<td>&gt;25</td>
<td>&gt;25</td>
<td>+8</td>
</tr>
<tr>
<td>(G9C RNase 1)⁻⁸</td>
<td>ND</td>
<td>16 ± 3</td>
<td>&lt;1.4</td>
<td>1.5 ± 0.1</td>
<td>4.6 ± 19</td>
<td>+9</td>
</tr>
<tr>
<td>ONC</td>
<td>90</td>
<td>0.0018 ± 0.00005</td>
<td>&gt;150⁴</td>
<td>0.22 ± 0.01</td>
<td>0.22 ± 5</td>
<td>+5</td>
</tr>
<tr>
<td>(S72C ONC)⁻⁸</td>
<td>ND</td>
<td>0.012 ± 0.00005</td>
<td>ND</td>
<td>0.79 ± 0.05</td>
<td>2.8 ± 16</td>
<td>+16</td>
</tr>
</tbody>
</table>

* Values $T_m$ (±2 °C) in 1 × DPBS and determined by UV spectroscopy.  
  † Per active-site values of $k_{cat}/K_M$ (±SE) for catalysis of 6-FAM-dArU(dA)₂-6-TAMRA cleavage in 1 × DPBS containing BSA (0.1 mg/mL) at (20 ± 2) °C.  
  ‡ Per active-site values of $K_i$ (±SE) for the complex with RI at (20 ± 2) °C.  
  § Per molecule values of IC50 (±SE) for incorporation of [methyl-³H]thymidine into the RNA of K-562 cells exposed to a ribonuclease and calculated with eq 3.  
  † Per active-site values of IC50 calculated by multiplying the IC50 value by the number of monomers in the conjugate.  
  † From ref 64.  
  † From ref 45.  
  † From ref 37 and determined by circular dichroism spectroscopy.  
  † Value of $K_i$ from ref 12.  
  † ND, not determined.

A novel assay was developed to determine the stoichiometry of RI-binding. The ability of the ribonuclease conjugates to cleave a fluorogenic substrate following preincubation with varying concentrations of RI was assayed. Apparent $K_i$ values were obtained by applying eq 2 to the data in Figure 3.

The G88R and K31A/D38R/R39D/N67R/G88R variants of RNase A had $K_i$’ values of 41.4 pM and 103 nM, respectively. (G88C RNase A)₃⁻⁸ exhibited $K_i$’ values of 0.94 nM, which is 23-fold higher than that of G88R RNase A. Near physiological concentrations of RI, the fractional activity of the trimeric conjugate reached a plateau at ~0.31. This value is consistent with one of the three active sites in the trimer remaining inaccessible to micromolar concentrations of RI. (G88C RNase A)₃⁻⁸ behaved in a nearly identical manner to (G88C RNase A)₅⁻⁸ (data not shown). Conversely, (A19C RNase A)₃⁻⁸, which differs from (G88C RNase A)₃⁻⁸ only in that it is restrictively tethered through a residue outside of the interface with RI, is inhibited tightly and completely by RI with $K_i$’ = 17 pM. This value is close to the concentration of enzymic active sites present in the assay solution (15 pM), and thus merely represents an upper limit for the $K_i$’ value (65).

(G88C RNase A)₃⁻³ was more readily inhibited by RI than was (G88C RNase A)₅⁻⁸, with $K_i$’ = 0.40 nM. Interestingly, the fractional activity of this dimer also reached a plateau at micromolar concentrations of RI, though the significance of its relative activity (~0.11) is obvious. Nonetheless, we conclude that trimers in the cytosol would retain a larger amount of unfettered ribonuclease activity than would dimers.

Cytotoxicity in Vitro. The toxicity of each ribonuclease was measured toward the K-562 human leukemia cell line. IC50 values are given in Table 1 on both a conjugate and an active-site basis, and were derived by applying eq 3 to the data in Figure 4. The results and fitted curves in Figure 4 are based upon the concentration of the entire conjugate, not just the active sites, and those will be the IC50 values discussed herein unless indicated otherwise. ONC and G88R RNase A displayed IC50 values similar to those reported previously (37, 38). (A19C RNase A)₃⁻⁸ exhibited no cytotoxic activity, even at concentrations of 20 µM (Figure 4A). This lack of cytotoxicity is consistent with its preserved sensitivity to RI and underscores the importance of constraining the ribonucleases by tethering within the RI–RNase A interface. G88C RNase A–NEM (IC50 = 28 µM; Figure 4A) was nearly 10-fold less cytotoxic than G88R RNase A. This substantial decrease in cytotoxic activity was surprising because of their nearly identical affinities for RI (G88C RNase A)₃⁻³ (IC50 = 11 µM) was 3-fold less toxic to K-562 cells than was G88R RNase A (Figure 4A) despite its substantially greater resistance to inhibition by RI in vitro (Figure 3).

The differential effects on cytotoxicity of linking two molecules of G88C RNase A ortho, meta, or para to each other about a phenyl ring is shown in Figure 4B. Surprisingly, the relatively subtle chemical differences led to detectable and reproducible differences in cytotoxicity. The IC50 values exhibited by (G88C RNase A)₃⁻⁴, (G88C RNase A)₃⁻⁵, and (G88C RNase A)₃⁻⁶ were 10, 14, and 27 µM, respectively, consistent with our hypothesis that more restrictive tethering endows greater cytotoxicity.

Three homologous mammalian ribonucleases, RNase A, RNase 1, and BS-RNase, were tethered with linker 8 through analogous residues within their β4–β5 surface loop. The resulting trimers were tested for their ability to inhibit the
proliferation of K-562 cells (Figure 4C). As reported previously [44], RNase 1 had no effect on the proliferation of K-562 cells. Per conjugate molecule, the (G88C RNase A)\textsubscript{3}-\textsubscript{8} conjugate (IC\textsubscript{50} = 8.6 \(\mu\)M) was more cytotoxic than any of the dimeric conjugates of RNase A linked through the same residue. (G89C RNase 1)\textsubscript{3}-\textsubscript{8} (IC\textsubscript{50} = 1.5 \(\mu\)M) and (C31A/C32A/G88C BS-RNase)\textsubscript{3}-\textsubscript{8} (IC\textsubscript{50} = 0.78 \(\mu\)M) were even more cytotoxic than the analogous RNase A trimer.

ONC and D38R/R39D/N67R/G88R RNase A are monomeric ribonucleases that are highly cytotoxic (IC\textsubscript{50} = 0.27 and 0.19 \(\mu\)M, respectively) because they are insensitive to RI [38]. The cytotoxic activities of trimeric conjugates of these two ribonucleases are shown in Figure 4D. Both (S72C ONC)\textsubscript{3}-\textsubscript{8} (IC\textsubscript{50} = 0.79 \(\mu\)M) and (D38R/R39D/N67R/G88R RNase A)\textsubscript{3}-\textsubscript{8} (IC\textsubscript{50} = 1.0 \(\mu\)M) are less cytotoxic than their monomers. On a per active-site basis, the cytotoxic activity of ONC and D38R/R39D/N67R/G88R RNase A is reduced by 10- and 17-fold, respectively, upon trimer formation.

Xenograft Mouse Studies. DU 145 prostate carcinoma cells are known to be sensitive to RI-evasive variants of RNase A [38]. To establish an effective dose and administration schedule, mice bearing DU 145 prostate carcinoma tumors were treated with K7A/D38R/R39D/G88R RNase A and ONC. A dose of 15 mg/kg (i.p., qd \(\times\) 5) was identified as being optimal for eliciting the maximum inhibition of tumor growth (TGI = 83%; Figure 5A) while displaying minimal off-target effects as monitored by change in body weight (Figure 5A inset). Indeed, this dose of K7A/D38R/R39D/G88R RNase A inhibits the growth of DU 145 tumors in mice as well as the effective dose of ONC (5 mg/kg; i.p., \(1 \times\) wk) (Figure 5B). Although the mice treated with the RNase A variant received 15-fold more ribonuclease (by mass) on a weekly basis than did those treated with ONC, the mammalian ribonuclease seems to be better tolerated, as indicated by the large decrease in body weight of the animals in the ONC treatment group during the course of the experiment (Figure 5B inset).

The importance of frequent administration of K7A/D38R/R39D/G88R RNase A to achieve maximal tumor growth inhibition is shown in Figure 5C. These mice received 75 mg/kg (1 \(\times\) wk) instead of the previous 15 mg/kg (qd \(\times\) 5). Although equivalent on a mass/week basis, once-weekly administration of K7A/D38R/R39D/G88R RNase A was dramatically less effective at inhibiting tumor growth (TGI = 15% versus 83%).

Next, mice were treated with a trimeric ribonuclease: (G88C RNase A)\textsubscript{3}-\textsubscript{8}. A dose of 25 mg/kg (1 \(\times\) wk) of (G88C RNase A)\textsubscript{3}-\textsubscript{8}, which is a third of the ribonuclease by mass that was used in the experiments depicted in Figure 5C, was administered to mice bearing DU 145 tumors. This dose led to a dramatic
inhibition of tumor growth (TGI = 75%; Figure 5D), despite the infrequent administration.

Xenograft studies were continued with A549 lung adenocarcinoma cells, which are less sensitive than DU 145 cells to Rl-evasive variants of RNase A (38). A dose of 25 mg/kg (1 × wk) of (G88C RNase A)3−8 inhibited the growth of these tumors substantially (TGI = 68%; Figure 6A). Photographs of mice from the vehicle and treatment groups upon completion of the experiment show the large reduction in the size of the tumors in treated animals (Figure 6B).

The human conjugate, (G89C RNase 1)3−8, was also administered to mice bearing A549 tumors. Although a dose of 7.5 mg/kg (1 × wk) inhibited tumor growth only slightly (TGI = 30%) (Figure 6C), a 10-fold higher dose of 75 mg/kg (1 × wk) inhibited the growth of these tumors at a high level (TGI = 79%) that was indistinguishable from that of a 100 mg/kg (2 × wk) dose of erlotinib hydrochloride. This tyrosine kinase inhibitor was approved in 2004 for the treatment of non-small cell lung cancer (66). It is noteworthy that a single molecule of the human ribonuclease conjugate achieved the same efficacy as ∼300 molecules of erlotinib.

Hydrodynamic Radius. The hydrodynamic radius of RNase A conjugates was assessed by gel-filtration chromatography. As expected, the radii decreased in the order trimer > dimers > monomers (Figure 7), suggesting that trimers persist longest in plasma circulation.

DISCUSSION

Thiol-reactive cross-linking reagents have found broad utility in a wide range of applications (55, 67, 68). For example, these reagents have been used as “molecular rulers” to probe the structure of large macromolecular complexes (69–74). Inspired by dimeric linkers 4–6, we synthesized the novel trimeric linker 7 (Scheme 1), expecting its phenyl scaffold to afford an even more constrained linkage than trer linker 8.

Preservation of Ribonucleolytic Activity. The enzymatic activity of RNase A is known to diminish upon nonspecific cross-linking with diimido esters (21). In contrast, site-specific tethering did not have a deleterious effect on the catalytic activity of any of the ribonucleases herein (Table 1). Indeed, (S72C RNase A)3−8 exhibited increased activity. The low catalytic activity of ONC is thought to originate in its low affinity for substrate (58). The increased charge density could accelerate the rate of substrate association.

Linkage Position. Site-specific tethering can allow or disallow a biomolecular interaction. We prepared two trimeric conjugates of RNase A, (A19C RNase A)3−8 and (G88C RNase A)3−8, that differ only at their site of linkage (Figure 2). Residue 19 lies within the α1–α2 loop of RNase A. Tethering three ribonuclease moieties there can readily accommodate the binding of three molecules of RI with high affinity (K’f ≤ 17 pM; Figure 3). This preservation of sensitivity to RI is corroborated by the results of the competition binding assay (K’f ≥ 1.4 nM; Table 1). In marked contrast, one active site of (G88C RNase A)3−8 remains free to degrade cellular RNA in the presence of micromolar RI (Figure 3). This evasion of RI endows (G88C RNase A)3−8 with toxicity for K-562 cells (Figure 4). This result is consistent with the report of Yamada and co-workers, who spliced human basic fibroblast growth factor (bFGF) into human pancreatic ribonuclease (RNase 1) as a separate domain (75). RI-evasion, and thus efficacy as an immunotoxin, was greater when the bFGF graft was inserted between residues 89 and 90, as opposed to residues 19 and 20, which are structurally analogous to the linkage positions explored in this work (H. Tada, personal communication).
Antitumor Activity of Ribonuclease Multimers

Linker Conformation. A motivation of our work was to characterize ribonuclease multimers that were tethered more restrictively than those prepared with linker 2. All of the bifunctional reagents tested yielded dimeric ribonuclease conjugates that were indeed more RI-evasive than (G88C RNase A)\textsubscript{2} (Table 1). Moreover, all but one of the reagents (6) yielded ribonuclease dimers that were more effective at inhibiting the proliferation of K-562 cells than was (G88C RNase A)\textsubscript{2}. The novel linker 7 likewise yielded more RI-evasive trimers (∼2-fold) than those prepared with its more flexible congener, 8. Surprisingly, the greater ability of (G88C RNase A)\textsubscript{3}−7 to evade RI did not translate into greater cytotoxicity.

Net Molecular Charge and Cytotoxicity. RNase A (Z = +4), RNase 1 (Z = +6), and BS-RNase (Z = +9) are highly cationic proteins with >80% amino acid sequence identity and comparable ribonucleolytic activity, yet (G88C RNase A)\textsubscript{3}−8, (G89C RNase 1)\textsubscript{3}−8, and (C31A/C32A/G88C BS-RNase)\textsubscript{3}−8 possess significantly different net charges: Z\textsubscript{4+}, +19, and +28, respectively. A correlation of net charge with cytotoxicity (76–79) is apparent in the trimeric ribonuclease conjugates, which have IC\textsubscript{50} values of 8.6, 1.5, and 0.78 µM, respectively (Table 1; Figure 4C).

Molecular Size and Cytotoxicity. The hydrodynamic radius of the ribonuclease conjugates changes in a predictable manner (Figure 7). Previously, we showed that the quaternary structure of BS-RNase was a liability to its cytotoxic activity, as monomeric variants of BS-RNase that evade RI are more cytotoxic than are dimers of the same variants (42). Likewise, trimerization of D38R/R39D/N67R/G88R RNase A and ONC, which evade RI as monomers, reduces their cytotoxicity by 10- and 17-fold, respectively (Table 1). What is the basis for this decrease? The cellular uptake of fluorescent latex beads of discrete size was found to correlate inversely with size (80). Although these beads were 50–500 nm in diameter and thus larger than our conjugates, our data suggest that the correlation between cellular uptake and molecular size extends to smaller entities as well.

Molecular Size and Circulation. The glomerular capillary wall acts as a molecular sieve, removing small proteins (e.g., proteohormones) from plasma circulation but retaining large ones (e.g., albumin and IgG antibodies). In both mice and rats, the half-life of intravenously administered monomeric ribonucleases is 2–5 min (23, 25, 81), which is similar to the glomerular filtration rate (81, 82). For a particular molecule, this rate is determined largely by molecular size; only when molecular size approaches that of the filtration pore do other attributes, such as molecular charge, have an appreciable

Figure 6. Effect of trimeric ribonuclease conjugates on tumor volume and body weight (insets) of Balb c(−/−) mice in xenograft models bearing human A549 lung tumors. Data points are the mean (±SE) for n mice; % TGI values in parentheses were calculated with eq 5. Vehicle control (○; n = 7). (A) (G88C RNase A)\textsubscript{3}−8 (▲, 25 mg/kg; i.p., 1 × wk, n = 7) and cisplatin (□, 6 mg/kg; i.p., 1 × wk, n = 7). (B) Photographs of representative mice treated with vehicle (left) or (G88C RNase A)−8 (right) on day 70 of the experiment in panel A. (C) (G89C RNase 1)\textsubscript{3}−8 (▼, 7.5 mg/kg; ▲, 75 mg/kg; i.p., 1 × wk, n = 7) and erlotinib (□, 100 mg/kg; p.o., 2 × wk, n = 7).

Figure 7. Elution profile of monomeric, dimeric, and trimeric ribonucleases from gel-filtration chromatography.
Dimeric ribonucleases exhibit a longer half-life in circulating therapeutics. Conjugates of mammalian ribonucleases as human cancer work demonstrates the potential of nonreducible, covalent administered less frequently and at a lower dose. Thus, this tumor growth in tumor-bearing mouse models, but could be highly evasive monomeric variants of RNase A at inhibiting linker G88C RNase 1 prepared with linker cleases. Finally, trimeric conjugates of G88C RNase A and conformational stability are preserved in tethered ribonucleases (Figure 7), their rapid clearance is not surprising (8). Capasso, S., Giordano, F., Mattia, C. A., Mazzarella, L., and Raines, R. T. (2005) On the track of RNase A: Revealing structure-function relationships with semisynthesis. J. Am. Chem. Soc. 117, 8057–8060.

A ribonuclease A variant with low catalytic activity but high cytotoxicity. J. Biol. Chem. 275, 9893–9896.

Quantitative evaluation of the lengths of homobifunctional protein cross-linking dimerases.


Biological actions of the oligomers of ribonuclease A. Cell. Mol. Life Sci. 61, 2431–2436.


Biopolymers 22, 25, 81.

Refined 1.7 Å X-ray crystallographic structure of P-30 protein, an amphibian ribonuclease with anti-tumor activity. J. Mol. Biol. 236, 1141–1153.


Thiol-reactive homobifunctional linkers (six dimeric and two trimeric), we have demonstrated that the cytotoxic activity of ribonuclease multimers correlates with how well they evade RI. Importantly, the catalytic activity and conformational stability are preserved in tethered ribonucleases. Finally, trimeric conjugates of G88C RNase A and G89C RNase 1 prepared with linker 8 were as effective as highly evasive monomeric variants of RNase A at inhibiting tumor growth in tumor-bearing mouse models, but could be administered less frequently and at a lower dose. Thus, this work demonstrates the potential of nonreducible, covalent conjugates of mammalian ribonucleases as human cancer therapeutics.

ACKNOWLEDGMENT

This work was supported by grant R01 CA073808 (NIH). We are grateful to L. D. Lavis for advice on the synthesis of linker 7, G. A. Ellis for the production and purification of RI, and J. Kalia, B. D. Smith, R. J. Johnson, G. A. Ellis, L. D. Lavis, and R. F. Turcotte for contributive discussions. T.I.R. was supported by Biotechnology Training Grant 08349 (NIH) and a William R. & Dorothy E. Sullivan Wisconsin Distinguished Graduate Fellowship. The Biophysics Instrumentation Facility was established with grants BIR-9512577 (NSF) and S10 RR13790 (NIH). The Keck Center for Chemical Genomics was established with a grant from the W.M. Keck Foundation. NMRFAM was supported by grant P41 RR2301 (NIH).

Supporting Information Available: Figures S1 and S2. This material is available free of charge via the Internet at http://pubs.acs.org.

LITERATURE CITED


linking reagents used as molecular rulers. *Protein Sci.* 10, 1293–1304.


